Dahua Jixian Upgrades China Biotech Sector to 'Overweight', Names Innovent, Hansoh, and Sino Biopharmaceutical as Top Picks

Gelonghui June 19 | UOB Kay Hian published a research report stating that China's biotechnology industry has entered an accelerated growth phase. Companies are expanding their innovative commercial product portfolios, achieving significant out-licensing deals, and attaining higher-than-expected profitability. Continuous policy support and globalization efforts will further drive the industry’s expansion. The firm believes that the industry will continue to perform well, with the potential for sustainable growth in the coming years, and has upgraded its rating for the sector to "Overweight." The firm highlighted Innovent Bio, Hansoh Pharma, and Sino Biopharm as its top picks.